Patents protect scientific discoveries and are an essential link between basic research and new therapeutics.
Currently Available Licensing Opportunities:
1) Use of an IL-12 receptor splice variant and molecular assay to quantify expression thereof (US patent 8,394,593)
2) SM38 Nucleic Acid Molecules (US patent 7,695,933)
3) Use of an IL-12 receptor-beta 1 splice variant to diagnose active tuberculosis (US patent 8,877,212)
To learn more the technologies listed above, please click the associated links or contact:
Atsuo Kuki, Ph.D.
President & Director